Navigation Links
Naviscan Positron Emission Mammography Technology Highlighted at the Society of Nuclear Medicine Annual Meeting
Date:6/18/2010

SAN DIEGO, June 18 /PRNewswire/ -- Naviscan's Positron Emission Mammography (PEM) technology was the focus of several presentations and discussions at the Society of Nuclear Medicine Annual Meeting in Salt Lake City.  The focus represents a growing interest and validation of how PEM can play an important role in the fight against breast cancer.  

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment. Other imaging systems, such as mammography and ultrasound, show only the location, not the metabolic phase. PEM scanners, which are about the size of an ultrasound system, are manufactured by Naviscan, Inc. and have been commercially available since 2007.

A presentation with considerable attention was of the release of the findings from the NIH-sponsored clinical study comparing PEM with breast MRI. This multi-site study (NIH Grant 5R44CA103102) of hundreds of women with newly diagnosed breast cancer shows that PEM may reduce unnecessary breast biopsies. The study found that PEM was significantly more precise at identifying benign and cancerous lesions, in what scientists call "Positive Predictive Value" or "PPV," therefore reducing the number of unnecessary biopsies.

Other presentations on PEM were led by leading researchers from M.D. Anderson Cancer Center, Johns Hopkins, Swedish Cancer Institute, University of Washington and Boston University.  These presentations covered not only the clinical advantages of PEM today, but also exciting new areas of focus.  

The triple negative cancer study results were particularly welcomed news.  The study enrolled 281 patients with newly diagnosed breast cancer and the results suggested that PEM may be able to properly characterize triple negative tumors.  Triple negative breast cancers make up between 13-38% of all breast cancers and are the most difficult to treat because they are so aggressive.

About Naviscan, Inc.

Naviscan, Inc., founded in 1995, develops and markets compact, high-resolution PET scanners for organ-specific molecular imaging and PET-guided radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.  For more information, call 1.858.587.3641 or visit www.naviscan.com.


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
2. Baylor Adds Naviscan PEM Technology to Womens Imaging Center
3. Johns Hopkins Medicine Acquires Naviscan PEM Technology for Novel Radiotracer Research
4. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
5. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
6. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
7. New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors
8. Alliance Imaging Offers Mobile Positron Emission Mammography (PEM) Imaging to its Florida Customers
9. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
10. Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
11. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... India , February 10, 2016 ... The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Trends, Technologies, Participants, and Environment" research report indicates ... worth over $149 billion by 2020 growing at ... up of companion diagnostics and targeted therapeutics and ...
(Date:2/9/2016)... Feb. 9, 2016  Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... its fiscal 2016 first quarter ended December 31, 2015. ... Fiscal 2016 First Quarter Highlights , Revenue of ... quarter of 2015 , Domestic Radiation Measurement services revenues ...
(Date:2/9/2016)... , Feb. 9, 2016  Jazz Pharmaceuticals plc ... report its 2015 fourth quarter and full year financial ... of the financial markets.  Company management will host a ... p.m. EST/9:30 p.m. GMT to discuss fourth quarter and ... and financial update and guidance for 2016 financial results. ...
Breaking Medicine Technology:
(Date:2/9/2016)... Altamonte Springs, FL (PRWEB) , ... February 09, ... ... nation’s leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It ... donations for each prescription referral received at our specialty pharmacy. , “Since ...
(Date:2/9/2016)... ... , ... The Journal of Pain Research has published the commentary ... As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention has ... patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the literature; ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... to expand access to affordable hearing aids , increase industry transparency, and ... in the United States. , “For the average consumer, the hearing aid industry ...
(Date:2/9/2016)... Maui, Hawaii (PRWEB) , ... February 09, 2016 , ... ... to Maui to lead a photographic adventure on the island, June 14-19, 2016, hosted ... Unforgettable Events series. , After a successful debut in 2015, the ...
(Date:2/9/2016)... ... February 09, 2016 , ... i2i Systems, an early innovator and developer of ... in the latest KLAS report, Population Health Management 2015: How Far Can Your Vendor ... population health management (PHM). The latest KLAS Report, leveraging over 200 user interviews, ...
Breaking Medicine News(10 mins):